RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9
RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers the price target from $10 to $9.
Read original at benzingaStocks · News reference
Opus Genetics Says Last Patient Enrolled In Registrational Phase 3 Clinical Trial Evaluating OPGx-LCA5, Investigational Gene Therapy For LCA5-Associated Inherited Retinal Disease
Topline six-month efficacy data expected by end of 2027Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) programOpus Genetics may submit a BLA based on
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 11:06 AM
- Checked
- Aug 3, 2026, 11:06 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Opus Genetics Files Prospectus To Sell $300M Mixed Securities Shelf Including 34.5M Shares
Common StockPreferred StockDebt SecuritiesWarrantsUnitsand up to 34,449,749 Shares of Common Stock Issuable Upon Exercise ofWarrants and Pre-Funded Warrants Offered, from time to time, by OpusGenetics, Inc.
Read original at benzingaOpus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate
Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the
Read original at benzinga8-K filing — Opus Genetics, Inc. (IRD)
Filed: 2026-08-06 AccNo: 0001628280-26-053824 Size: 248 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar